Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  NeuroReport

• Publication date

  1994-12-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00001756-199412000-00063PMID 7696626
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neurotensin effects on evoked release of dopamine in slices from striatum, nucleus accumbens and prefrontal cortex in rat

  2004cited by this paper
• Riluzole and experimental parkinsonism: partial antagonism of MPP+-induced increase in striatal extracellular dopamine in rats in vivo

  1994cited by this paper
• The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson's disease.

  1994cited by this paper
• NMDA antagonists partially protect against MPTP induced neurotoxicity in mice

  1993cited by this paper
• The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1.

  1993cited by this paper
• MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum.

  1993cited by this paper
• MK‐801 Fails to Protect Against the Dopaminergic Neuropathology Produced by Systemic 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine in Mice or Intranigral 1‐Methyl‐4‐Phenylpyridinium in Rats

  1992cited by this paper
• Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice.

  1992cited by this paper
• Partial protective effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice.

  1992cited by this paper
• MK‐801 Prevents 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Induced Parkinsonism in Primates

  1992cited by this paper
• Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

  1991cited by this paper
• Cocaine displaces [3H]WIN 35,428 binding to dopamine uptake sites in vivo more rapidly than mazindol or GBR 12909.

  1991cited by this paper
• Compensations after lesions of central dopaminergic neurons: some clinical and basic implications.

  1990cited by this paper
• Pharmacological Studies on Lamotrigine, A Novel Potential Antiepileptic Drug

  1986cited by this paper
• 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--II. Biochemical properties.

  1985cited by this paper
• Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

  1985cited by this paper
• Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.

  1985cited by this paper
• Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism

  1984cited by this paper
• Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

  1984cited by this paper
• Effect of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) on monoamine neurotransmitters in mouse brain & heart.

  1984cited by this paper
• A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1983cited by this paper
• Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

  1983cited by this paper
• Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.

  1979cited by this paper
• METHYLHISTAMINE: EVIDENCE FOR SELECTIVE DEAMINATION BY MAO B IN THE RAT BRAIN IN VIVO

  1977cited by this paper

• Absence of a synergic nigral proapoptotic effect triggered by REM sleep deprivation in the rotenone model of Parkinson´s disease

  2019cites this paper
• NEUROPROTEKCIJA U PARKINSONOVOJ BOLESTI

  2014cites this paper
• Acoplamiento molecular in silico revela posibles sitios de unión entre Riluzol y el canal de sodio Nav1.6 implicaciones para la estrategia de diseño de fármacos en el síndrome de Esclerosis Lateral Amiotrofica

  2012cites this paper
• Neuroprotection in Parkinson's Disease: A Systematic Review of thePreclinical Data

  2012influential citation
• Riluzole neuroprotection in a parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation

  2012cites this paper
• A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in Amyotrophic Lateral Sclerosis

  2012cites this paper
• Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.

  2010cites this paper
• Strategies for the protection of dopaminergic neurons against neurotoxicity

  2009cites this paper
• The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs

  2009cites this paper
• The evolution of pharmacological treatment for Parkinson's disease.

  2008cites this paper
• Current clinical trials in amyotrophic lateral sclerosis

  2007cites this paper
• New Therapeutic Approaches to Parkinson’s Disease Including Neural Transplants

  2005cites this paper
• AmyotropfUc Lateral sclerosis

  2004cites this paper
• Designing neuroprotection trials in Parkinson's disease

  2003influential citation
• Modern therapeutic approaches in Parkinson's disease

  2003cites this paper
• Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.

  2003cites this paper
• Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis.

  2003cites this paper
• Morbus Parkinson und Neuroprotektion: Traum oder Realität?

  2003cites this paper
• Effect of chronic treatment with riluzole on the nigrostriatal dopaminergic system in weaver mutant mice.

  2002cites this paper
• Toxin-induced mitochondrial dysfunction.

  2002cites this paper
• Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence

  2002cites this paper
• Parkinson's disease.

  2002cites this paper
• Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6‐OHDA lesion in the rat brain

  2001cites this paper
• Neuroprotective effects of (±)‐kavain in the MPTP mouse model of Parkinson's disease

  2001cites this paper
• Neuroprotective effect of riluzole in MPTP-treated mice.

  2001cites this paper
• Experimental models of Parkinson's disease

  2001cites this paper
• Neuroprotective properties of 17β‐estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice

  2001cites this paper
• Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.

  2001cites this paper
• Involvement of Non-Dopaminergic Pathways in Parkinson’s Disease

  2000cites this paper
• Protective effect of riluzole on MPTP-induced depletion of dopamine and its metabolite content in mice

  2000cites this paper
• Implication of the Subthalamic Nucleus in the Pathophysiology and Pathogenesis of Parkinson's Disease

  2000cites this paper
• Preventing levodopa-induced dyskinesias.

  2000cites this paper
• Comparison of the novel drug Ensaculin with MK-801 on the reduction of hydroxyl radical production in rat striatum after local application of glutamate.

  2000cites this paper
• The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation.

  2000cites this paper
• The role of excitotoxicity in neurodegenerative disease: implications for therapy.

  1999cites this paper
• Therapeutic advances in idiopathic Parkinsonism.

  1999cites this paper
• Therapeutic developments in amyotrophic lateral sclerosis.

  1999cites this paper
• Antiglutamate therapy of ALS--which is the next step?

  1999cites this paper
• The role of excitotoxicity in neurodegenerative disease: implications for therapy.

  1999cites this paper
• Antioxidative and Proapoptotic Effects of Riluzole on Cultured Cortical Neurons

  1999cites this paper
• Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons.

  1998cites this paper
• Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.

  1998cites this paper
• Riluzole, a glutamate release inhibitor, and motor behavior

  1998cites this paper
• Experimental Models of Parkinson's Disease: From the Static to the Dynamic

  1998cites this paper
• Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection

  1998cites this paper
• Effects of α‐Phenyl‐tert‐Butylnitrone and Selegiline on Hydroxyl Free Radicals in Rat Striatum Produced by Local Application of Glutamate

  1998cites this paper
• Pharmacology: Ouabain‐induced Increase in Dopamine Release from Mouse Striatal Slices is Antagonized by Riluzole

  1998cites this paper
• Excitotoxicity and nitric oxide in parkinson's disease pathogenesis

  1998cites this paper
• Glutamate toxicity in chronic neurodegenerative disease.

  1998cites this paper
• [Riluzole as a treatment for amyotrophic lateral sclerosis].

  1998cites this paper
• Prodystonic effects of riluzole in an animal model of idiopathic dystonia related to decreased total power in the red nucleus?

  1997cites this paper
• Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration.

  1997cites this paper
• A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.

  1997cites this paper
• Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.

  1997cites this paper
• 3−Nitropropionic Acid Exacerbates [3H]GABA Release Evoked by Glucose Deprivation in Rat Striatal Slices

  1996cites this paper
• Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.

  1996cites this paper
• A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in Amyotrophic Lateral Sclerosis

  1996cites this paper
• Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat.

  1996cites this paper
• babapenun in a Transgenic Model of ~dd AmyotropfUc Lateral sclerosis

  1996cites this paper
• The pharmacology and mechanism of action of riluzole

  1996cites this paper
• Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis

  1996cites this paper
• Excitatory amino acid receptors and neurodegeneration.

  1995cites this paper
• Effects of complete and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat.

  1995cites this paper
• Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study.

  1995cites this paper
• Methamphetamine and dopamine neurotoxicity: differential effects of agents interfering with glutamatergic transmission.

  1995cites this paper